Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific ABCA4 ABCA4, ABCR , ARMD2, CORD3, FFM, RP19, STGD, STGD1 ENSG00000198691 ATP-binding cassette, sub-family A (ABC1), member 4 1 93992835-94121132 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level Lung cancer:2.45e-4 (favourable), Urothelial cancer:2.72e-4 (unfavourable) Tissue enhanced Tissue enhanced epididymis: 9.7 kidney: 4.1 ABCB7 ABC7, ASAT, Atm1p, EST140535 ENSG00000131269 ATP-binding cassette, sub-family B (MDR/TAP), member 7 X 75053172-75156732 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA034982 Approved Supported Mitochondria Renal cancer:5.31e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 21.3 ABCB9 EST122234 ENSG00000150967 ATP-binding cassette, sub-family B (MDR/TAP), member 9 12 122920951-122981649 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB033052, HPA035113, HPA035114 Approved Supported Vesicles Glioma:4.62e-4 (unfavourable) Mixed Tissue enhanced testis: 23.9 cerebral cortex: 12.1 ACER1 ASAH3 ENSG00000167769 Alkaline ceramidase 1 19 6306142-6333629 Enzymes, Predicted membrane proteins Evidence at transcript level Group enriched Tissue enriched 6 skin: 68.0 esophagus: 11.4 ADCY7 AC7, KIAA0037 ENSG00000121281 Adenylate cyclase 7 16 50246137-50318135 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041218, HPA048241 Uncertain Approved Cytosol Cervical cancer:5.31e-4 (unfavourable) Mixed Mixed spleen: 42.9 ADCY8 AC8, ADCY3, HBAC1 ENSG00000155897 Adenylate cyclase 8 (brain) 8 130780301-131042426 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018652, HPA024291 Supported Group enriched Group enriched 8 cerebral cortex: 12.9;epididymis: 27.3;fallopian tube: 6.2 lung,seminal vesicle: 1.9 ADGRG2 EDDM6, GPR64, HE6, TM7LN2 ENSG00000173698 Adhesion G protein-coupled receptor G2 X 18989309-19122637 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA001478, HPA050029 Supported Approved Plasma membrane
Cytosol Tissue enhanced Tissue enriched 6 epididymis: 1469.4 parathyroid gland: 235.5 AGMO FLJ16237, TMEM195 ENSG00000187546 Alkylglycerol monooxygenase 7 15200318-15562015 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057900 Uncertain Vesicles Tissue enriched Tissue enhanced liver: 63.6 epididymis: 17.5 ALG3 CDGS4, D16Ertd36e, Not56, NOT56L ENSG00000214160 ALG3, alpha-1,3- mannosyltransferase 3 184242301-184249548 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA045103 Approved Liver cancer:1.58e-5 (unfavourable), Lung cancer:8.67e-5 (unfavourable), Renal cancer:1.25e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 32.7 ALG8 MGC2840 ENSG00000159063 ALG8, alpha-1,3-glucosyltransferase 11 78100936-78139660 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA051898 Approved Approved Nucleoplasm Expressed in all Expressed in all testis: 85.6 ANO1 DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A ENSG00000131620 Anoctamin 1, calcium activated chloride channel 11 70078302-70189528 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA032148 Supported Renal cancer:4.09e-6 (unfavourable), Endometrial cancer:4.58e-6 (favourable), Head and neck cancer:7.28e-5 (unfavourable), Pancreatic cancer:1.70e-4 (unfavourable), Lung cancer:2.40e-4 (unfavourable) Expressed in all Tissue enhanced epididymis: 217.7;seminal vesicle: 295.7 skin: 116.0 ANO10 FLJ10375, MGC47890, SCAR10, TMEM16K ENSG00000160746 Anoctamin 10 3 43354859-43691594 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051569 Approved Renal cancer:6.41e-6 (favourable), Endometrial cancer:1.11e-4 (favourable), Liver cancer:3.19e-4 (unfavourable), Colorectal cancer:6.70e-4 (favourable) Expressed in all Expressed in all duodenum: 64.3 ANO2 C12orf3, TMEM16B ENSG00000047617 Anoctamin 2, calcium activated chloride channel 12 5531869-5946232 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036276 Supported Nucleoplasm
Plasma membrane Tissue enhanced Tissue enhanced testis: 17.7 placenta: 5.9 ANO8 KIAA1623, TMEM16H ENSG00000074855 Anoctamin 8 19 17323223-17334829 Predicted membrane proteins Evidence at protein level HPA031787, HPA049206 Uncertain Uncertain Nucleoplasm
Nucleoli fibrillar center Expressed in all Tissue enhanced cerebral cortex: 34.6 skin: 20.0 ATP11B ATPIF, ATPIR, KIAA0956 ENSG00000058063 ATPase, class VI, type 11B 3 182793500-182921635 Enzymes, Predicted membrane proteins, Transporters Evidence at protein level HPA036237, HPA036238 Uncertain Approved Microtubule organizing center
Cytosol Pancreatic cancer:1.09e-4 (unfavourable), Endometrial cancer:3.44e-4 (unfavourable) Expressed in all Expressed in all testis: 57.7 ATP1A2 FHM2, MHP2 ENSG00000018625 ATPase, Na+/K+ transporting, alpha 2 polypeptide 1 160115759-160143591 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB022230 Approved Tissue enriched Group enriched 6 cerebral cortex: 435.6;skeletal muscle: 307.1 heart muscle: 59.1 ATP2A1 ATP2A, SERCA1 ENSG00000196296 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 16 28878405-28904509 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002310, CAB032706 Supported Approved Endoplasmic reticulum Tissue enhanced Tissue enriched 95 skeletal muscle: 2782.7 esophagus: 29.2 ATP2B1 PMCA1 ENSG00000070961 ATPase, Ca++ transporting, plasma membrane 1 12 89588049-89709300 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB005605, HPA011166, HPA012945 Supported Supported Plasma membrane Liver cancer:7.74e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 144.0 ATP6V0A4 a4, ATP6N1B, ATP6N2, RDRTA2, RTA1C, RTADR, Stv1, Vph1, VPP2 ENSG00000105929 ATPase, H+ transporting, lysosomal V0 subunit a4 7 138706295-138799560 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA018029, HPA064555 Supported Approved Cytosol Renal cancer:1.32e-6 (favourable) Tissue enriched Group enriched 9 kidney: 69.1;salivary gland: 31.8 breast: 5.5 ATP7A MNK ENSG00000165240 ATPase, Cu++ transporting, alpha polypeptide X 77910656-78050395 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA012887, HPA048107 Approved Supported Golgi apparatus
Vesicles Renal cancer:8.38e-4 (favourable) Expressed in all Mixed parathyroid gland: 15.0 ATP7B WND ENSG00000123191 ATPase, Cu++ transporting, beta polypeptide 13 51930436-52012125 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA009137, HPA013187 Supported Supported Golgi apparatus Endometrial cancer:5.01e-4 (unfavourable) Mixed Mixed testis: 14.0 CACNA1A APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6 ENSG00000141837 Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 19 13206442-13623990 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA064258 Supported Approved Nucleoplasm
Golgi apparatus
Vesicles Pancreatic cancer:4.32e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 18.1 stomach: 6.4 CLN3 BTS, JNCL ENSG00000188603 Ceroid-lipofuscinosis, neuronal 3 16 28477279-28495575 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA063280 Uncertain Expressed in all Expressed in all placenta: 54.9 CLN8 C8orf61, EPMR, FLJ39417 ENSG00000182372 Ceroid-lipofuscinosis, neuronal 8 8 1755778-1786572 Disease related genes, Predicted membrane proteins Evidence at protein level Renal cancer:4.36e-8 (favourable) Expressed in all Expressed in all placenta: 10.8 COQ2 CL640, FLJ26072 ENSG00000173085 Coenzyme Q2 4-hydroxybenzoate polyprenyltransferase 4 83261536-83284914 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA056599, HPA068727 Approved Approved Cytosol Expressed in all Expressed in all adrenal gland: 18.5 COX10 ENSG00000006695 COX10 heme A:farnesyltransferase cytochrome c oxidase assembly factor 17 14069496-14208677 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA032005, HPA032006 Supported Supported Nucleoli
Mitochondria
Cytosol Renal cancer:4.32e-6 (favourable), Stomach cancer:8.73e-4 (favourable) Expressed in all Expressed in all testis: 43.0 COX15 CEMCOX2 ENSG00000014919 Cytochrome c oxidase assembly homolog 15 (yeast) 10 99711844-99732100 Disease related genes, Predicted membrane proteins Evidence at protein level HPA037727, HPA037728, HPA066096 Uncertain Supported Mitochondria Renal cancer:9.21e-6 (favourable) Expressed in all Expressed in all thyroid gland: 36.2 DGAT1 ARGP1, DGAT ENSG00000185000 Diacylglycerol O-acyltransferase 1 8 144314584-144326910 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB032853 Supported Approved Nucleoli
Endoplasmic reticulum Expressed in all Tissue enhanced duodenum: 73.2;small intestine: 76.7 adipose tissue: 20.0 EDNRB ETB, HSCR, HSCR2 ENSG00000136160 Endothelin receptor type B 13 77895481-77919768 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB017842, HPA027546 Approved Approved Plasma membrane
Cytosol Renal cancer:7.20e-5 (favourable) Group enriched Tissue enhanced placenta: 178.8 cerebral cortex: 89.1 FZD1 DKFZp564G072 ENSG00000157240 Frizzled class receptor 1 7 91264364-91271326 Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB013008 Approved Supported Plasma membrane Renal cancer:8.87e-7 (favourable) Expressed in all Mixed thyroid gland: 32.3 G6PC G6PT, GSD1a ENSG00000131482 Glucose-6-phosphatase, catalytic subunit 17 42900797-42913369 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA052324 Approved Renal cancer:3.79e-5 (favourable), Liver cancer:5.42e-5 (favourable) Tissue enriched Tissue enhanced kidney: 88.4;liver: 146.8 small intestine: 33.8 G6PC2 IGRP ENSG00000152254 Glucose-6-phosphatase, catalytic, 2 2 168901240-168910000 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Tissue enriched Tissue enriched 13 pancreas: 2.9 testis: 0.2 GPAA1 GAA1, hGAA1 ENSG00000197858 Glycosylphosphatidylinositol anchor attachment 1 8 144082590-144086216 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Expressed in all Expressed in all parathyroid gland: 68.8 GPR108 LUSTR2 ENSG00000125734 G protein-coupled receptor 108 19 6729914-6737603 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041924, HPA041951, HPA063863 Uncertain Supported Golgi apparatus
Vesicles Renal cancer:1.29e-9 (favourable), Endometrial cancer:1.04e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 73.7 GPR37L1 ETBR-LP-2 ENSG00000170075 G protein-coupled receptor 37 like 1 1 202122858-202133592 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA064454 Supported Tissue enriched Tissue enriched 61 cerebral cortex: 34.2 seminal vesicle: 0.5 GPR89A UNQ192 ENSG00000117262 G protein-coupled receptor 89A 1 145607990-145670648 Predicted membrane proteins Evidence at protein level HPA076096 Approved Endoplasmic reticulum Mixed Mixed kidney: 20.8 GPRC5C RAIG-3 ENSG00000170412 G protein-coupled receptor, class C, group 5, member C 17 74424851-74451653 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA029776 Supported Uncertain Nucleus
Microtubule organizing center
Cytosol Renal cancer:1.58e-5 (favourable) Expressed in all Mixed thyroid gland: 103.7 HHAT FLJ10724, GUP2, MART-2, MART2, rasp, sit, ski, Skn ENSG00000054392 Hedgehog acyltransferase 1 210328252-210676296 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016462 Approved Approved Golgi apparatus Renal cancer:8.47e-7 (favourable) Expressed in all Mixed thyroid gland: 7.8 HMGCR ENSG00000113161 3-hydroxy-3-methylglutaryl-CoA reductase 5 75336329-75362104 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008338, CAB016797 Approved Renal cancer:9.42e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 87.8 ITPR3 IP3R3 ENSG00000096433 Inositol 1,4,5-trisphosphate receptor, type 3 6 33620365-33696574 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA003915, HPA064704 Approved Uncertain Vesicles Expressed in all Mixed skin: 65.2 KCNT1 KCa4.1, KIAA1422, SLACK, Slo2.2 ENSG00000107147 Potassium channel, sodium activated subfamily T, member 1 9 135702185-135795508 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA059880 Uncertain Tissue enhanced Group enriched 5 cerebral cortex: 11.7;ovary: 3.9;skeletal muscle: 3.9;spleen: 6.7 testis: 1.2 LMF1 C16orf26, FLJ12681, FLJ22302, JFP11, TMEM112, TMEM112A ENSG00000103227 Lipase maturation factor 1 16 853634-981318 Disease related genes, Predicted membrane proteins Evidence at protein level Renal cancer:7.95e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 22.7 MBOAT4 FKSG89, GOAT, OACT4 ENSG00000177669 Membrane bound O-acyltransferase domain containing 4 8 30131824-30144686 Predicted membrane proteins Evidence at protein level HPA044509 Supported Golgi apparatus Tissue enhanced Tissue enhanced fallopian tube: 3.0;stomach: 3.5 gallbladder: 1.6 MBOAT7 BB1, hMBOA-7, LENG4, LPIAT ENSG00000125505 Membrane bound O-acyltransferase domain containing 7 19 54173412-54189882 Enzymes, Predicted membrane proteins Evidence at protein level HPA055967 Approved Approved Cytosol Liver cancer:5.55e-6 (unfavourable), Renal cancer:6.62e-5 (unfavourable), Urothelial cancer:4.31e-4 (favourable), Lung cancer:5.13e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 24.3 MFSD10 IT10C3, TETRAN ENSG00000109736 Major facilitator superfamily domain containing 10 4 2930561-2934859 Predicted membrane proteins Evidence at protein level HPA043209 Uncertain Approved Nucleoplasm
Nuclear membrane Renal cancer:5.68e-5 (unfavourable), Liver cancer:4.49e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 41.3 MFSD7 FLJ22269, LP2561 ENSG00000169026 Major facilitator superfamily domain containing 7 4 681829-689441 Predicted membrane proteins Evidence at transcript level HPA043593 Uncertain Renal cancer:2.66e-5 (favourable) Expressed in all Mixed parathyroid gland: 14.3 MYADM ENSG00000179820 Myeloid-associated differentiation marker 19 53866223-53876437 Predicted membrane proteins, Transporters Evidence at protein level HPA056301 Approved Nuclear speckles Renal cancer:7.71e-7 (unfavourable), Lung cancer:8.15e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 257.6 MYADML2 LOC255275 ENSG00000185105 Myeloid-associated differentiation marker-like 2 17 81939645-81947233 Predicted membrane proteins Evidence at transcript level HPA041856, HPA048476 Uncertain Tissue enhanced Tissue enriched 20 skeletal muscle: 30.9 heart muscle: 1.5 NIPA2 ENSG00000140157 Non imprinted in Prader-Willi/Angelman syndrome 2 15 22838641-22868384 Predicted membrane proteins, Transporters Evidence at protein level HPA067160, HPA071342 Approved Approved Golgi apparatus Expressed in all Expressed in all appendix: 45.7 NIPAL4 ICHYN ENSG00000172548 NIPA-like domain containing 4 5 157460019-157474717 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038259 Approved Urothelial cancer:6.82e-4 (favourable) Tissue enhanced Tissue enhanced skin: 42.0 esophagus: 10.2 NOX5 NOX5A, NOX5B ENSG00000255346 NADPH oxidase, EF-hand calcium binding domain 5 15 68930525-69062743 Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enhanced spleen: 13.4 testis: 3.6 OR1D5 OR17-31 ENSG00000262628 Olfactory receptor, family 1, subfamily D, member 5 17 3062669-3063607 G-protein coupled receptors, Predicted membrane proteins No evidence Not detected Not detected all non-specific tissues: 0.0 OR1S1 OST034 ENSG00000172774 Olfactory receptor, family 1, subfamily S, member 1 (gene/pseudogene) 11 58214745-58215722 G-protein coupled receptors, Predicted membrane proteins No evidence HPA049304 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR2M2 OR2M2Q, OST423 ENSG00000198601 Olfactory receptor, family 2, subfamily M, member 2 1 248179986-248181029 G-protein coupled receptors, Predicted membrane proteins No evidence Not detected Not detected all non-specific tissues: 0.0 OR2T1 OR1-25 ENSG00000175143 Olfactory receptor, family 2, subfamily T, member 1 1 248405995-248407104 G-protein coupled receptors, Predicted membrane proteins No evidence HPA063064 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4C5 OR4C5P, OR4C5Q ENSG00000176540 Olfactory receptor, family 4, subfamily C, member 5 (gene/pseudogene) 11 48365485-48366465 G-protein coupled receptors, Predicted membrane proteins No evidence HPA049516 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR51G1 OR51G3P ENSG00000176879 Olfactory receptor, family 51, subfamily G, member 1 (gene/pseudogene) 11 4923374-4924339 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA050482 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR51J1 OR51J1P, OR51J2 ENSG00000184321 Olfactory receptor, family 51, subfamily J, member 1 (gene/pseudogene) 11 5402597-5403547 G-protein coupled receptors, Predicted membrane proteins No evidence HPA017605 Uncertain Not detected Not detected epididymis: 0.1 OR51Q1 ENSG00000167360 Olfactory receptor, family 51, subfamily Q, member 1 (gene/pseudogene) 11 5422111-5423206 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA044998 Uncertain Not detected Not detected epididymis: 0.1 OR52B6 ENSG00000187747 Olfactory receptor, family 52, subfamily B, member 6 11 5580877-5581884 G-protein coupled receptors, Predicted membrane proteins No evidence Not detected Not detected all non-specific tissues: 0.0 OR7G2 OST260 ENSG00000170923 Olfactory receptor, family 7, subfamily G, member 2 19 9102269-9103306 G-protein coupled receptors, Predicted membrane proteins No evidence Not detected Not detected all non-specific tissues: 0.0 OR8K3 ENSG00000181689 Olfactory receptor, family 8, subfamily K, member 3 (gene/pseudogene) 11 56318307-56319245 G-protein coupled receptors, Predicted membrane proteins No evidence Not detected Not detected all non-specific tissues: 0.0 PAQR5 FLJ20190, MPRG ENSG00000137819 Progestin and adipoQ receptor family member V 15 69298947-69407780 Predicted membrane proteins Evidence at protein level HPA076729 Approved Vesicles Renal cancer:1.47e-14 (favourable), Pancreatic cancer:2.15e-5 (unfavourable) Mixed Tissue enhanced kidney: 55.6 adrenal gland: 20.9 PAQR6 FLJ22672, PRdelta ENSG00000160781 Progestin and adipoQ receptor family member VI 1 156243321-156248117 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA073505 Approved Nucleus
Nucleoli Renal cancer:1.58e-8 (unfavourable), Colorectal cancer:1.60e-5 (unfavourable), Urothelial cancer:1.86e-4 (favourable), Prostate cancer:1.99e-4 (unfavourable) Tissue enriched Tissue enriched 9 cerebral cortex: 97.8 skin: 10.8 PAQR7 MPRA, mSR ENSG00000182749 Progestin and adipoQ receptor family member VII 1 25861210-25871253 Predicted membrane proteins Evidence at protein level HPA046936 Approved Approved Cytosol Renal cancer:1.05e-5 (favourable), Liver cancer:1.14e-4 (unfavourable) Expressed in all Mixed testis: 51.0 PAQR8 C6orf33, LMPB1, MPRB ENSG00000170915 Progestin and adipoQ receptor family member VIII 6 52361421-52407777 Predicted membrane proteins Evidence at protein level HPA064625 Supported Golgi apparatus
Plasma membrane Breast cancer:4.61e-4 (favourable), Urothelial cancer:6.40e-4 (favourable) Expressed in all Mixed cerebral cortex: 65.1 PAQR9 FLJ41938 ENSG00000188582 Progestin and adipoQ receptor family member IX 3 142949164-142963682 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052798 Uncertain Tissue enriched Tissue enhanced liver: 8.3;testis: 19.3 heart muscle: 5.2 PCNXL2 FLJ11383, KIAA0435 ENSG00000135749 Pecanex-like 2 (Drosophila) 1 232983435-233295713 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013815, HPA014427 Uncertain Approved Endoplasmic reticulum Renal cancer:2.27e-5 (unfavourable) Mixed Mixed cerebral cortex: 14.0 PHTF1 PHTF ENSG00000116793 Putative homeodomain transcription factor 1 1 113696831-113759489 Plasma proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA059486 Approved Nucleoli
Nuclear bodies Renal cancer:1.21e-6 (unfavourable) Expressed in all Tissue enhanced testis: 54.1 parathyroid gland: 18.8 PHTF2 DKFZp434D166 ENSG00000006576 Putative homeodomain transcription factor 2 7 77798792-77957503 Predicted membrane proteins, Transcription factors Evidence at protein level HPA012312 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:3.09e-7 (unfavourable), Thyroid cancer:2.78e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 60.8 PIGQ GPI1, hGPI1 ENSG00000007541 Phosphatidylinositol glycan anchor biosynthesis, class Q 16 566995-584136 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039105, HPA039828, HPA061414 Approved Approved Nucleoplasm
Golgi apparatus
Vesicles Renal cancer:2.53e-6 (favourable) Expressed in all Expressed in all bone marrow: 24.2 PIGV FLJ20477 ENSG00000060642 Phosphatidylinositol glycan anchor biosynthesis, class V 1 26787472-26798398 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054181 Approved Endoplasmic reticulum
Cytosol Renal cancer:7.60e-7 (favourable) Expressed in all Expressed in all testis: 83.5 PORCN DHOF, MG61, por, PORC, PPN ENSG00000102312 Porcupine homolog (Drosophila) X 48508962-48520814 Disease related genes, Predicted membrane proteins Evidence at protein level HPA049215, HPA058413 Approved Approved Vesicles Expressed in all Mixed adrenal gland: 34.6 PSEN1 AD3, FAD, PS1, S182 ENSG00000080815 Presenilin 1 14 73136418-73223691 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB006844, HPA030760, HPA067496 Approved Approved Nucleus
Golgi apparatus
Cell Junctions Renal cancer:1.52e-8 (favourable), Liver cancer:1.99e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 66.1 PSEN2 AD3L, AD4, PS2, STM2 ENSG00000143801 Presenilin 2 1 226870184-226896105 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB013634, HPA038005 Supported Nucleus Expressed in all Expressed in all parathyroid gland: 29.1 RXFP2 GPR106, GREAT, INSL3R, LGR8, RXFPR2 ENSG00000133105 Relaxin/insulin-like family peptide receptor 2 13 31739542-31803388 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level Not detected Not detected endometrium: 0.8 RYR1 CCO, MHS, MHS1, PPP1R137, RYR ENSG00000196218 Ryanodine receptor 1 (skeletal) 19 38433699-38587564 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA056416 Supported Approved Golgi apparatus
Vesicles
Cytosol Mixed Tissue enriched 30 skeletal muscle: 572.4 esophagus: 18.7 SCAP KIAA0199 ENSG00000114650 SREBF chaperone 3 47413694-47477126 Predicted membrane proteins Evidence at protein level HPA004713 Approved Renal cancer:4.33e-5 (favourable), Pancreatic cancer:7.14e-4 (favourable) Expressed in all Expressed in all adrenal gland: 67.3 SEC61A2 FLJ10578 ENSG00000065665 Sec61 translocon alpha 2 subunit 10 12129637-12169961 Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:1.08e-5 (favourable), Urothelial cancer:8.75e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 51.4 testis: 32.3 SLC10A1 NTCP ENSG00000100652 Solute carrier family 10 (sodium/bile acid cotransporter), member 1 14 69775417-69797289 Predicted membrane proteins, Transporters Evidence at protein level HPA042727 Approved Liver cancer:9.53e-6 (favourable) Tissue enriched Tissue enriched 392 liver: 212.1 gallbladder: 0.5 SLC10A2 ASBT, ISBT ENSG00000125255 Solute carrier family 10 (sodium/bile acid cotransporter), member 2 13 103043998-103066846 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA004795 Approved Renal cancer:5.78e-5 (favourable) Tissue enriched Group enriched 32 duodenum: 21.6;kidney: 15.3;small intestine: 52.2 gallbladder: 0.9 SLC10A3 DXS253E, P3 ENSG00000126903 Solute carrier family 10, member 3 X 154487306-154490690 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA021656 Approved Approved Intermediate filaments Colorectal cancer:4.15e-5 (unfavourable), Cervical cancer:4.53e-4 (favourable), Pancreatic cancer:7.22e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 33.2 SLC10A4 MGC29802 ENSG00000145248 Solute carrier family 10, member 4 4 48483343-48489196 Predicted membrane proteins, Transporters Evidence at protein level HPA028835 Uncertain Supported Tissue enhanced Tissue enhanced adrenal gland: 6.2;cerebral cortex: 4.0 cervix, uterine: 1.5 SLC10A6 SOAT ENSG00000145283 Solute carrier family 10 (sodium/bile acid cotransporter), member 6 4 86823468-86849263 Predicted membrane proteins Evidence at protein level HPA016662 Supported Group enriched Tissue enhanced esophagus: 11.0;skin: 17.3 adipose tissue: 6.2 SLC14A1 HsT1341, JK, RACH1, RACH2 ENSG00000141469 Solute carrier family 14 (urea transporter), member 1 (Kidd blood group) 18 45724127-45752520 Blood group antigen proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA058353, HPA059570 Supported Supported Vesicles Group enriched Group enriched 5 prostate: 132.1;urinary bladder: 51.9 cerebral cortex: 18.2 SLC16A3 MCT3, MCT4 ENSG00000141526 Solute carrier family 16 (monocarboxylate transporter), member 3 17 82228397-82261129 Predicted membrane proteins, Transporters Evidence at protein level CAB017490, HPA021451 Approved Supported Nuclear membrane
Plasma membrane Liver cancer:1.19e-7 (unfavourable), Renal cancer:3.71e-7 (unfavourable), Lung cancer:2.02e-5 (unfavourable), Cervical cancer:6.07e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 74.4 SLC17A2 NPT3 ENSG00000112337 Solute carrier family 17, member 2 6 25912754-25930726 Predicted membrane proteins, Transporters Evidence at protein level HPA038270 Uncertain Liver cancer:8.54e-4 (favourable) Tissue enriched Tissue enriched 85 liver: 40.9 kidney,testis: 0.4 SLC1A3 EA6, EAAT1, GLAST ENSG00000079215 Solute carrier family 1 (glial high affinity glutamate transporter), member 3 5 36606355-36688334 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002573, HPA037467, HPA037468 Supported Approved Nucleoli
Mitochondria Tissue enriched Tissue enriched 16 cerebral cortex: 519.6 adipose tissue: 31.7 SLC22A11 OAT4 ENSG00000168065 Solute carrier family 22 (organic anion/urate transporter), member 11 11 64555626-64572875 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA026076 Approved Renal cancer:3.68e-5 (favourable) Group enriched Group enriched 134 epididymis: 10.0;kidney: 25.9;placenta: 44.5 seminal vesicle: 0.2 SLC22A12 OAT4L, RST, URAT1 ENSG00000197891 Solute carrier family 22 (organic anion/urate transporter), member 12 11 64590641-64602353 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA024575 Supported Renal cancer:2.63e-4 (favourable) Group enriched Tissue enriched 195 kidney: 104.6 adipose tissue: 0.5 SLC22A18 BWR1A, BWSCR1A, IMPT1, ITM, ORCTL2, SLC22A1L, TSSC5 ENSG00000110628 Solute carrier family 22, member 18 11 2899721-2925246 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA067812, HPA071461 Approved Expressed in all Tissue enhanced duodenum: 44.5;small intestine: 32.4 colon: 10.5 SLC22A23 C6orf85, FLJ22174 ENSG00000137266 Solute carrier family 22, member 23 6 3268962-3457022 Predicted membrane proteins, Transporters Evidence at protein level HPA014697 Approved Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:2.39e-4 (unfavourable), Endometrial cancer:6.57e-4 (favourable) Expressed in all Expressed in all stomach: 28.2 SLC23A3 FLJ31168, SVCT3, Yspl1 ENSG00000213901 Solute carrier family 23, member 3 2 219161465-219170095 Predicted membrane proteins, Transporters Evidence at protein level HPA019059 Approved Nucleus
Cell Junctions Tissue enriched Tissue enhanced kidney: 52.7;small intestine: 23.3 duodenum: 9.0 SLC24A1 CSNB1D, HsT17412, KIAA0702, NCKX, NCKX1, RODX ENSG00000074621 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 15 65611366-65660995 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039370 Supported Approved Microtubules Renal cancer:2.33e-6 (favourable) Expressed in all Mixed fallopian tube: 8.7 SLC24A4 NCKX4 ENSG00000140090 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 4 14 92322581-92501483 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Group enriched Tissue enhanced cerebral cortex: 7.1 spleen: 2.7 SLC26A8 ENSG00000112053 Solute carrier family 26 (anion exchanger), member 8 6 35943514-36024868 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA038080, HPA038081 Uncertain Not detected Tissue enriched 27 testis: 75.6 bone marrow: 2.8 SLC2A14 GLUT14, SLC2A3P3 ENSG00000173262 Solute carrier family 2 (facilitated glucose transporter), member 14 12 7812512-7891148 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA006539 Approved Approved Plasma membrane Tissue enriched Tissue enriched 9 testis: 151.1 breast: 17.2 SLC35A1 CMPST, hCST ENSG00000164414 Solute carrier family 35 (CMP-sialic acid transporter), member A1 6 87470623-87512336 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:2.70e-6 (unfavourable) Expressed in all Expressed in all prostate: 59.9 SLC35A2 UGALT, UGAT, UGT, UGT1, UGT2, UGTL ENSG00000102100 Solute carrier family 35 (UDP-galactose transporter), member A2 X 48903180-48911958 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036087 Approved Supported Golgi apparatus Liver cancer:9.64e-5 (unfavourable), Breast cancer:3.16e-4 (unfavourable), Stomach cancer:8.23e-4 (favourable) Expressed in all Expressed in all fallopian tube: 44.1 SLC35A3 ENSG00000117620 Solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), member A3 1 99969789-100026979 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA015253 Uncertain Expressed in all Expressed in all rectum: 47.2 SLC35A4 ENSG00000176087 Solute carrier family 35, member A4 5 140564456-140569103 Predicted membrane proteins, Transporters Evidence at protein level HPA062210 Approved Nucleoplasm Renal cancer:4.56e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 110.8 SLC35B2 UGTrel4 ENSG00000157593 Solute carrier family 35 (adenosine 3'-phospho 5'-phosphosulfate transporter), member B2 6 44254096-44257890 Predicted membrane proteins, Transporters Evidence at protein level HPA029638 Approved Approved Vesicles Liver cancer:8.59e-5 (unfavourable), Prostate cancer:6.07e-4 (favourable), Breast cancer:7.90e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 58.0 SLC35B4 FLJ14697, YEA4 ENSG00000205060 Solute carrier family 35 (UDP-xylose/UDP-N-acetylglucosamine transporter), member B4 7 134289332-134317051 Predicted membrane proteins Evidence at protein level HPA049779 Approved Expressed in all Mixed cerebral cortex: 17.9 SLC35D2 SQV7L, UGTrel8 ENSG00000130958 Solute carrier family 35 (UDP-GlcNAc/UDP-glucose transporter), member D2 9 96320706-96383710 Predicted membrane proteins, Transporters Evidence at protein level HPA064047 Approved Validated Golgi apparatus Expressed in all Expressed in all small intestine: 73.8 SLC35E1 FLJ14251 ENSG00000127526 Solute carrier family 35, member E1 19 16549831-16572382 Predicted membrane proteins, Transporters Evidence at protein level HPA016570, HPA062214 Approved Validated Golgi apparatus Expressed in all Expressed in all parathyroid gland: 29.2 SLC35F1 C6orf169, dJ230I3.1 ENSG00000196376 Solute carrier family 35, member F1 6 117907526-118317676 Predicted membrane proteins, Transporters Evidence at protein level HPA019576 Approved Approved Nucleoplasm
Microtubule organizing center
Cytosol Group enriched Tissue enriched 12 cerebral cortex: 45.6 epididymis: 3.7 SLC35F2 FLJ13018 ENSG00000110660 Solute carrier family 35, member F2 11 107790991-107928293 Predicted membrane proteins, Transporters Evidence at protein level HPA048185, HPA050695 Uncertain Approved Mitochondria Pancreatic cancer:5.92e-6 (unfavourable), Lung cancer:4.03e-4 (unfavourable), Glioma:7.31e-4 (favourable) Expressed in all Mixed prostate: 33.0 SLC35F4 C14orf36, FLJ37712 ENSG00000151812 Solute carrier family 35, member F4 14 57563922-57982194 Predicted membrane proteins, Transporters Evidence at transcript level HPA043853 Uncertain Approved Nucleoli fibrillar center Not detected Tissue enhanced prostate: 1.9;seminal vesicle: 4.9;testis: 1.8 thyroid gland: 1.0 SLC36A1 LYAAT-1, PAT1, TRAMD3 ENSG00000123643 Solute carrier family 36 (proton/amino acid symporter), member 1 5 151437046-151492381 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035937 Approved Renal cancer:1.83e-6 (unfavourable), Liver cancer:6.30e-5 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 64.1 duodenum: 45.5 SLC36A2 PAT2, TRAMD1, tramdorin ENSG00000186335 Solute carrier family 36 (proton/amino acid symporter), member 2 5 151314978-151347590 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA044002, HPA062229 Supported Tissue enriched Group enriched 26 kidney: 67.2;skeletal muscle: 28.1 testis: 1.8 SLC38A2 ATA2, KIAA1382, SAT2, SNAT2 ENSG00000134294 Solute carrier family 38, member 2 12 46358189-46372867 Predicted membrane proteins Evidence at protein level HPA035180 Approved Approved Vesicles Expressed in all Expressed in all skin: 239.3 SLC38A5 JM24, SN2 ENSG00000017483 Solute carrier family 38, member 5 X 48458537-48470256 Predicted membrane proteins, Transporters Evidence at protein level HPA047411 Approved Approved Vesicles
Plasma membrane
Cytosol Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:2.13e-4 (unfavourable) Expressed in all Mixed pancreas: 50.0 SLC39A1 ZIP1, ZIRTL ENSG00000143570 Solute carrier family 39 (zinc transporter), member 1 1 153959099-153968184 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA016506 Uncertain Cytosol Liver cancer:4.12e-7 (unfavourable), Head and neck cancer:5.26e-5 (unfavourable), Cervical cancer:4.83e-4 (unfavourable) Expressed in all Expressed in all placenta: 133.4 SLC39A3 ZIP3 ENSG00000141873 Solute carrier family 39 (zinc transporter), member 3 19 2732204-2740152 Predicted membrane proteins, Transporters Evidence at protein level HPA042139, HPA058526 Uncertain Approved Vesicles Endometrial cancer:9.76e-5 (favourable) Expressed in all Expressed in all testis: 109.9 SLC41A3 FLJ20473 ENSG00000114544 Solute carrier family 41, member 3 3 126006355-126101561 Predicted membrane proteins, Transporters Evidence at protein level HPA045847 Approved Supported Plasma membrane Liver cancer:1.49e-7 (unfavourable), Renal cancer:6.04e-7 (favourable) Expressed in all Expressed in all testis: 79.0 SLC43A2 MGC34680 ENSG00000167703 Solute carrier family 43 (amino acid system L transporter), member 2 17 1569267-1628886 Predicted membrane proteins, Transporters Evidence at protein level HPA021564 Approved Pancreatic cancer:1.05e-6 (favourable), Renal cancer:5.40e-5 (favourable) Expressed in all Tissue enhanced placenta: 31.6 appendix: 17.4 SLC52A3 bA371L19.1, C20orf54, hRFT2, RFVT3 ENSG00000101276 Solute carrier family 52 (riboflavin transporter), member 3 20 760080-776015 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA049391 Approved Stomach cancer:5.51e-6 (favourable) Expressed in all Tissue enhanced testis: 62.2 small intestine: 18.5 SLC9B2 FLJ23984, NHA2, NHEDC2 ENSG00000164038 Solute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2 4 103019868-103085829 Predicted membrane proteins, Transporters Evidence at protein level HPA047008 Uncertain Approved Nucleoplasm
Cell Junctions Expressed in all Tissue enhanced cerebral cortex: 32.6 liver: 20.5 SLCO1A2 OATP, OATP-A, OATP1A2, SLC21A3 ENSG00000084453 Solute carrier organic anion transporter family, member 1A2 12 21264600-21419594 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA071152 Approved Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 28.8 salivary gland: 6.6 SPPL2A IMP3, PSL2 ENSG00000138600 Signal peptide peptidase like 2A 15 50702266-50765808 Enzymes, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036062, HPA067304 Supported Supported Vesicles Expressed in all Expressed in all parathyroid gland: 285.5 SURF4 ERV29, FLJ22993, MGC102753 ENSG00000148248 Surfeit 4 9 133361449-133376166 Predicted membrane proteins Evidence at protein level HPA064613 Approved Head and neck cancer:1.47e-5 (unfavourable), Breast cancer:5.85e-4 (unfavourable), Liver cancer:8.11e-4 (unfavourable) Expressed in all Expressed in all small intestine: 84.4 TAAR6 TA4, TRAR4 ENSG00000146383 Trace amine associated receptor 6 6 132570322-132571359 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level Not detected Not detected kidney: 0.1 TAP2 ABCB3, D6S217E, PSF2, RING11 ENSG00000204267 Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 6 32821833-32838780 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA001312 Approved Approved Nuclear speckles
Endoplasmic reticulum Renal cancer:5.22e-8 (unfavourable), Pancreatic cancer:1.51e-4 (unfavourable) Expressed in all Mixed urinary bladder: 15.7 TAS2R60 T2R60 ENSG00000185899 Taste receptor, type 2, member 60 7 143443453-143444409 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA030416 Uncertain Not detected Not detected appendix,bone marrow,liver,parathyroid gland,placenta: 0.1 TCIRG1 a3, Atp6i, ATP6N1C, ATP6V0A3, OC-116, OC116, TIRC7 ENSG00000110719 T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3 11 68039016-68050895 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038742 Approved Approved Mitochondria Renal cancer:1.50e-11 (unfavourable), Urothelial cancer:9.45e-6 (favourable) Expressed in all Expressed in all spleen: 83.5 TM6SF1 ENSG00000136404 Transmembrane 6 superfamily member 1 15 83107407-83144854 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016051, HPA056857 Uncertain Approved Intermediate filaments Renal cancer:6.79e-4 (favourable) Mixed Mixed thyroid gland: 13.2 TM6SF2 Lpr4 ENSG00000213996 Transmembrane 6 superfamily member 2 19 19264364-19273391 Predicted membrane proteins Evidence at protein level HPA066026 Uncertain Tissue enhanced Group enriched 5 duodenum: 79.1;small intestine: 78.4 liver: 14.6 TM7SF2 ANG1, DHCR14A, NET47 ENSG00000149809 Transmembrane 7 superfamily member 2 11 65111845-65116384 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030691, HPA072704 Approved Supported Endoplasmic reticulum
Vesicles Renal cancer:8.49e-8 (favourable) Expressed in all Expressed in all adrenal gland: 161.3 TMBIM1 LFG3, PP1201, RECS1 ENSG00000135926 Transmembrane BAX inhibitor motif containing 1 2 218274192-218292586 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012093, HPA070824 Approved Supported Vesicles Renal cancer:3.38e-4 (favourable), Pancreatic cancer:4.22e-4 (unfavourable) Expressed in all Expressed in all esophagus: 270.8 TMC5 FLJ13593 ENSG00000103534 Transmembrane channel-like 5 16 19410496-19499113 Predicted membrane proteins Evidence at protein level HPA040810, HPA042037 Approved Approved Nucleus
Plasma membrane Liver cancer:7.96e-4 (unfavourable) Mixed Tissue enhanced small intestine: 60.2 duodenum: 46.6 TMEM117 DKFZp434K2435 ENSG00000139173 Transmembrane protein 117 12 43835967-44389762 Predicted membrane proteins Evidence at transcript level HPA046223 Uncertain Melanoma:3.94e-4 (unfavourable) Expressed in all Mixed seminal vesicle: 7.2 TMEM161A FLJ20422, FLJ39645 ENSG00000064545 Transmembrane protein 161A 19 19119169-19138513 Predicted membrane proteins Evidence at protein level HPA043365 Approved Approved Cytosol Stomach cancer:2.99e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 20.9 TMEM161B MGC33214 ENSG00000164180 Transmembrane protein 161B 5 88189633-88269476 Predicted membrane proteins Evidence at protein level HPA044562 Uncertain Expressed in all Expressed in all parathyroid gland: 58.9 TMEM175 MGC4618 ENSG00000127419 Transmembrane protein 175 4 932387-958656 Predicted membrane proteins, Transporters Evidence at protein level HPA057160 Approved Approved Nucleus
Nuclear membrane Pancreatic cancer:9.85e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 20.8 TMEM181 GPR178, KIAA1423 ENSG00000146433 Transmembrane protein 181 6 158536436-158635428 Predicted membrane proteins Evidence at protein level HPA040189 Approved Approved Golgi apparatus
Vesicles Ovarian cancer:1.09e-4 (unfavourable), Cervical cancer:7.26e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 41.5 TMEM184C FLJ10846, TMEM34 ENSG00000164168 Transmembrane protein 184C 4 147617383-147672044 Predicted membrane proteins Evidence at protein level HPA054013 Uncertain Approved Nucleoplasm
Vesicles Renal cancer:2.31e-7 (favourable), Pancreatic cancer:6.37e-4 (unfavourable) Expressed in all Group enriched 5 parathyroid gland: 253.7;thyroid gland: 54.5 placenta: 28.5 TMEM185A CXorf13, FAM11A, FRAXF ENSG00000269556 Transmembrane protein 185A X 149596556-149631912 Predicted membrane proteins Evidence at protein level HPA048295, HPA071744 Uncertain Approved Endoplasmic reticulum Expressed in all Expressed in all ovary: 36.3 TMEM185B FAM11B, FLJ20979 ENSG00000226479 Transmembrane protein 185B 2 120221278-120223408 Predicted membrane proteins Evidence at protein level HPA048295, HPA071744 Uncertain Approved Endoplasmic reticulum Liver cancer:5.71e-7 (unfavourable), Endometrial cancer:4.96e-6 (unfavourable), Colorectal cancer:5.44e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 61.4 TMEM260 C14orf101, FLJ20392 ENSG00000070269 Transmembrane protein 260 14 56488354-56650606 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003502 Uncertain Approved Nucleus
Focal adhesion sites
Cytosol Lung cancer:7.11e-4 (favourable) Expressed in all Tissue enhanced cervix, uterine: 63.2 thyroid gland: 14.0 TMEM39B FLJ10315 ENSG00000121775 Transmembrane protein 39B 1 32072031-32102866 Predicted membrane proteins Evidence at protein level HPA040191, HPA040224 Approved Approved Vesicles Renal cancer:5.11e-9 (unfavourable), Liver cancer:2.82e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 9.7 TMEM45B BC016153, FLJ40787 ENSG00000151715 Transmembrane protein 45B 11 129815819-129860003 Predicted membrane proteins Evidence at protein level HPA015878 Approved Uncertain Nucleoplasm
Cytosol Expressed in all Tissue enhanced duodenum: 140.0;small intestine: 141.9 rectum: 104.8 TMEM86A FLJ90119 ENSG00000151117 Transmembrane protein 86A 11 18693122-18704785 Predicted membrane proteins Evidence at transcript level HPA057119 Uncertain Expressed in all Mixed skin: 13.3 TRAM1 TRAM, TRAMP ENSG00000067167 Translocation associated membrane protein 1 8 70573442-70608387 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA023929 Approved Cervical cancer:2.06e-4 (unfavourable), Renal cancer:7.79e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 316.6 TRAM1L1 MGC26568 ENSG00000174599 Translocation associated membrane protein 1-like 1 4 117083554-117085576 Predicted membrane proteins Evidence at transcript level HPA044560 Uncertain Approved Mitochondria Mixed Mixed cerebral cortex: 14.2 TRPC1 HTRP-1 ENSG00000144935 Transient receptor potential cation channel, subfamily C, member 1 3 142724074-142807888 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB009387, HPA021130 Supported Approved Vesicles Renal cancer:2.72e-5 (unfavourable) Mixed Mixed endometrium: 18.5 TRPC3 ENSG00000138741 Transient receptor potential cation channel, subfamily C, member 3 4 121879027-121951754 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA037969 Uncertain Not detected Tissue enhanced smooth muscle: 4.1 cerebral cortex: 2.1 TRPC4 HTRP4, TRP4 ENSG00000133107 Transient receptor potential cation channel, subfamily C, member 4 13 37636636-37870425 Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Mixed Tissue enhanced endometrium: 18.5;seminal vesicle: 12.0;smooth muscle: 18.2 prostate: 10.7 TRPC6 FSGS2, TRP6 ENSG00000137672 Transient receptor potential cation channel, subfamily C, member 6 11 101451564-101872562 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA045098, HPA062164 Approved Approved Nucleoplasm
Cytosol Mixed Tissue enhanced placenta: 29.8 lung: 20.0 TRPM1 CSNB1C, LTRPC1, MLSN1 ENSG00000134160 Transient receptor potential cation channel, subfamily M, member 1 15 31001061-31161273 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA014779, HPA014785 Approved Uncertain Nucleoplasm
Cytosol Tissue enriched Group enriched 27 skin: 4.8;testis: 2.5 kidney: 0.1 TRPM3 GON-2, KIAA1616, LTRPC3 ENSG00000083067 Transient receptor potential cation channel, subfamily M, member 3 9 70529063-71446904 Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Tissue enhanced Tissue enhanced kidney: 17.5 testis: 6.3 TRPM8 ENSG00000144481 Transient receptor potential cation channel, subfamily M, member 8 2 233917398-234019522 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Liver cancer:7.15e-4 (favourable) Tissue enriched Tissue enriched 8 prostate: 128.7 liver: 16.3 UBIAD1 SCCD, TERE1 ENSG00000120942 UbiA prenyltransferase domain containing 1 1 11273206-11296049 Disease related genes, Predicted membrane proteins Evidence at protein level HPA044862 Approved Vesicles Renal cancer:6.80e-5 (favourable) Expressed in all Expressed in all fallopian tube: 15.7 VN1R2 V1RL2 ENSG00000196131 Vomeronasal 1 receptor 2 19 53258292-53261837 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA044551 Uncertain Not detected Mixed small intestine: 2.5 VN1R4 V1RL4 ENSG00000228567 Vomeronasal 1 receptor 4 19 53266676-53267723 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA027018 Uncertain Not detected Not detected testis: 0.5 WFS1 DFNA14, DFNA38, DFNA6, DIDMOAD, WFS ENSG00000109501 Wolfram syndrome 1 (wolframin) 4 6269849-6303265 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA029128 Approved Endometrial cancer:1.13e-6 (favourable), Thyroid cancer:3.13e-4 (unfavourable) Expressed in all Mixed ovary: 61.4 WLS C1orf139, EVI, FLJ23091, GPR177, mig-14, MRP, wls ENSG00000116729 Wntless Wnt ligand secretion mediator 1 68098473-68233120 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA069520 Approved Supported Endoplasmic reticulum Renal cancer:3.67e-7 (favourable), Urothelial cancer:3.51e-4 (unfavourable), Breast cancer:4.03e-4 (favourable), Ovarian cancer:9.43e-4 (favourable) Expressed in all Expressed in all epididymis: 160.7 XK Kx, NA, NAC, X1k, XKR1 ENSG00000047597 X-linked Kx blood group X 37685759-37732130 Blood group antigen proteins, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA019036 Approved Approved Nucleoplasm
Vesicles
Mitochondria Mixed Mixed rectum: 12.3 XKR3 MGC57211, XTES ENSG00000172967 XK, Kell blood group complex subunit-related family, member 3 22 16783412-16821699 Predicted membrane proteins, Transporters Evidence at transcript level HPA003379, HPA035081 Uncertain Not detected Tissue enriched 80 testis: 14.3 cerebral cortex: 0.1 XKR6 C8orf21, C8orf5, C8orf7 ENSG00000171044 XK, Kell blood group complex subunit-related family, member 6 8 10896045-11201366 Predicted membrane proteins Evidence at transcript level HPA024828 Uncertain Mixed Mixed testis: 1.8 XKR7 C20orf159, dJ310O13.4 ENSG00000260903 XK, Kell blood group complex subunit-related family, member 7 20 31968002-32003387 Predicted membrane proteins Evidence at protein level HPA040854 Uncertain Not detected Tissue enriched 10 cerebral cortex: 3.6 adrenal gland,testis: 0.3 XKR8 FLJ10307 ENSG00000158156 XK, Kell blood group complex subunit-related family, member 8 1 27959462-27968096 Predicted membrane proteins, Transporters Evidence at protein level HPA049984, HPA053529 Uncertain Approved Golgi apparatus Breast cancer:8.63e-4 (favourable) Expressed in all Expressed in all placenta: 13.6 XKR9 ENSG00000221947 XK, Kell blood group complex subunit-related family, member 9 8 70669365-70790371 Predicted membrane proteins, Transporters Evidence at transcript level HPA044430 Uncertain Approved Mitochondria Pancreatic cancer:7.20e-4 (unfavourable) Mixed Tissue enhanced testis: 14.1 small intestine: 6.2 XKRX XKR2, XPLAC ENSG00000182489 XK, Kell blood group complex subunit-related, X-linked X 100913445-100929433 Predicted membrane proteins, Transporters Evidence at transcript level Thyroid cancer:3.52e-4 (favourable) Mixed Tissue enhanced skin: 9.5 tonsil: 3.3 XPR1 SYG1, X3 ENSG00000143324 Xenotropic and polytropic retrovirus receptor 1 1 180632004-180890251 Disease related genes, Predicted membrane proteins Evidence at protein level HPA016557 Supported Approved Endoplasmic reticulum
Golgi apparatus Liver cancer:3.04e-4 (unfavourable) Expressed in all Expressed in all testis: 31.1 XXbac-BPG246D15.9 ENSG00000250264 6 32813767-32838822 Predicted membrane proteins Evidence at transcript level HPA001312 Approved Approved Nuclear speckles
Endoplasmic reticulum Not detected Tissue enhanced appendix: 16.0;spleen: 9.7 lymph node: 6.6